Scribd Logo
Upload

Welcome to Scribd!

  • Contributors - 2023 - Overcoming Obstacles in Drug Discovery and Development

    Uploaded by

    Papaiva Jr
    4 views2 pages
    This document lists over 80 contributors to the book. The contributors are from various academic institutions, pharmaceutical and biotechnology companies across the United States and Canada. They have expertise in areas related to drug metabolism, pharmacokinetics, toxicology and clinical pharmacology.

    Original Description:

    Original Title

    Contributors_2023_Overcoming-Obstacles-in-Drug-Discovery-and-Development

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This document lists over 80 contributors to the book. The contributors are from various academic institutions, pharmaceutical and biotechnology companies across the United States and Canada. They have expertise in areas related to drug metabolism, pharmacokinetics, toxicology and clinical pharmacology.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    4 views2 pages

    Contributors - 2023 - Overcoming Obstacles in Drug Discovery and Development

    Uploaded by

    Papaiva Jr
    This document lists over 80 contributors to the book. The contributors are from various academic institutions, pharmaceutical and biotechnology companies across the United States and Canada. They have expertise in areas related to drug metabolism, pharmacokinetics, toxicology and clinical pharmacology.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    Contributors

    Karim Azer, Axcella Therapeutics, Cambridge, MA, Jinping Gan, HiFiBiO Therapeutics, Cambridge, MA,
    United States United States; Drug Metabolism and Pharmacokinetics,
    Brian Barnes, Department of Business & Education, Bristol Myers Squibb Company, Lawrenceville, NJ,
    Foundation for Critical Thinking, Santa Barbara, CA, United States
    United States; Department of Philosophy, University of Kan He, Biotranex LLC, Princeton, NJ, United States
    Louisville, Louisville, KY, United States; Department Sara C. Humphreys, Pharmacokinetics and Drug Metab-
    of Philosophy, Indiana University Southeast, New olism Department, Amgen Research, South San Fran-
    Albany, IN, United States; Department of Philosophy, cisco, CA, United States
    Quality Leadership University, Panama City, Panama
    W. Griffith Humphreys, Aranmore Pharma Consulting,
    Jeff S. Barrett, Critical Path Institute, Tuscon, AZ, United Lawrenceville, NJ, United States
    States
    Graham Jang, Blaze Bioscience, Seattle, WA, United States
    Karen E. Brown, Department of Biomedical and Phar-
    maceutical Sciences, University of Montana, Missoula, Christopher Kirk, Research and Development, Kezar Life
    MT, United States; L.S. Skaggs Institute for Health Sciences, South San Francisco, CA, United States
    Innovation, University of Montana, Missoula, MT, Julie M. Lade, Pharmacokinetics and Drug Metabolism
    United States Department, Amgen Research, South San Francisco,
    Timothy J. Carlson, Carlson DMPK Consulting, LLC, CA, United States
    Belmont, CA, United States Shuguang Ma, Pharmacokinetics and Drug Metabolism,
    Hsuan Ping Chang, Department of Pharmaceutical Sci- Amgen Inc., South San Francisco, CA, United States
    ences, School of Pharmacy and Pharmaceutical Scien- Cynthia J. Musante, Pfizer, Cambridge, MA, United States
    ces, The State University of New York at Buffalo, Joshua T. Pearson, ADME & Discovery Toxicology,
    Buffalo, NY, United States Merck & Co., Inc., Kenilworth, NJ, United States
    Yuen Kiu Cheung, Department of Pharmaceutical Scien- Chandra Prakash, Department of Drug Metabolism,
    ces, School of Pharmacy and Pharmaceutical Sciences, Pharmacokinetics and Clinical Pharmacology, Agios
    The State University of New York at Buffalo, Buffalo, Pharmaceuticals, Cambridge, MA, United States
    NY, United States
    Brooke M. Rock, Pharmacokinetics and Drug Metabolism
    D.D. Christ, SNC Partners LLC, Annapolis, MD, United Department, Amgen Research, South San Francisco,
    States CA, United States
    Upendra P. Dahal, Department of Pharmacokinetics and Joseph M. Roesner, ADME & Discovery Toxicology,
    Drug Metabolism, Amgen Inc., Thousand Oaks, CA, Merck & Co., Inc., Kenilworth, NJ, United States
    United States
    Dhaval K. Shah, Department of Pharmaceutical Sciences,
    Deepak Dalvie, Bristol Myers Squibb, San Diego, CA, School of Pharmacy and Pharmaceutical Sciences, The
    United States State University of New York at Buffalo, Buffalo, NY,
    Arian Emami Riedmaier, PBPK Consultancy, Certara, United States
    Princeton, NJ, United States Hong Shen, Drug Metabolism and Pharmacokinetics,
    Paul W. Erhardt, DUP Emeritus, Medicinal Chemistry, Bristol Myers Squibb Company, Lawrenceville, NJ,
    University of Toledo, Sylvania, OH, United States United States
    Robert S. Foti, ADME & Discovery Toxicology, Merck & Sekhar Surapaneni, Bristol Myers Squibb, Summit, NJ,
    Co., Inc., Kenilworth, NJ, United States United States

    xi
    xii Contributors

    Mai B. Thayer, Pharmacokinetics and Drug Metabolism Harvey Wong, Faculty of Pharmaceutical Sciences, The
    Department, Amgen Research, South San Francisco, University of British Columbia., Vancouver, BC,
    CA, United States Canada
    Giridhar S. Tirucherai, Clinical Pharmacology and Simon G. Wong, Drug Metabolism and Pharmacokinetics,
    Pharmacometrics, Bristol Myers Squibb Company, Pliant Therapeutics, South San Francisco, CA, United
    Lawrenceville, NJ, United States States
    Mirjam Trame, University of Florida, Gainesville, FL, Erica L. Woodahl, Department of Biomedical and Phar-
    United States maceutical Sciences, University of Montana, Missoula,
    Jan L. Wahlstrom, Department of Pharmacokinetics and MT, United States; L.S. Skaggs Institute for Health
    Drug Metabolism, Amgen Inc., Thousand Oaks, CA, Innovation, University of Montana, Missoula, MT,
    United States United States
    Zhengping Wang, Nonclinical Development and Clinical Zheng Yang, Metabolism and Pharmacokinetics, Phar-
    Pharmacology, Revolution Medicines, Redwood City, maceutical Candidate Optimization, Bristol Myers
    CA, United States Squibb, Princeton, NJ, United States
    Larry C. Wienkers, Wienkers Consulting, LLC, Bain- Jinfu Yang, Research and Development, Zenshine Phar-
    bridge Island, WA, United States maceuticals Inc., Burlingame, CA, United States

    You might also like